AtriCure (ATRC) Tops Q2 EPS by 4c

AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $136.1 million versus the consensus estimate of $130.17 million.

GUIDANCE:

AtriCure sees FY2025 EPS of ($0.39)-($0.34), versus the consensus of ($0.51). AtriCure sees FY2025 revenue of $527-533 million, versus the consensus of $523 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Waller: Recent Increases In Core Inflation Are Quite Broad
• Permian Resources (PR) call put ratio 1 call to 10 puts with a focus on July 15 and 30 puts
• CG Oncology (CGON) call put ratio 1.4 calls to 1 put as share price down 4.4%